Opus Genetics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
IRD$4.23+0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(in thousands, except share and per share amounts)
| For the Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| License and collaborations revenue | $10,992 | $19,049 |
| Operating expenses: | ||
| General and administrative | 18,215 | 11,959 |
| Research and development | 26,851 | 17,653 |
| Acquired in-process research and development | 28,000 | — |
| Total operating expenses | 73,066 | 29,612 |
| Loss from operations | (62,074) | (10,563) |
| Financing costs (Note 7) | — | (1,328) |
| Fair value change in derivative liabilities | 72 | 80 |
| Other income, net | 4,470 | 1,837 |
| Loss before income taxes | (57,532) | (9,974) |
| Provision for income taxes | — | (12) |
| Net loss | (57,532) | (9,986) |
| Other comprehensive loss, net of tax | — | — |
| Comprehensive loss | $(57,532) | $(9,986) |
| Net loss per share (Note 11): | ||
| Basic and diluted | $(2.15) | $(0.46) |
| Number of shares used in per share calculations: | ||
| Basic and diluted | 26,715,526 | 21,589,821 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.